Simon De Gussem

A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75

Lidia Oostvogels, Azhar Alhatemi, Simon De Gussem, Ebbe Englev et autres

Group B Streptococcus (GBS) disease is an increasing medical burden in adults. The present phase 1 trial evaluated an adjuvanted GBS vaccine (GBS-AlpN) containing N-terminal domains of four alpha-like proteins (AlpNs) (Alp1N, Alp2/3 N, RibN and AlpCN) in 60 healthy adults and …

us, be, dk, gb (code pays fourni par la source)

LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults

Valentino D’Onofrio, Marjolein Verstraete, Sharon Porrez, Bart Jacobs et autres

be, nl, us (code pays fourni par la source)

LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults

Valentino D’Onofrio, Marjolein Verstraete, Sharon Porrez, Bart Jacobs et autres

Vaccine immunogenicity declines with age due to immunosenescence, underscoring the need for improved adjuvants. LiteVax Adjuvant (LVA), a squalane-in-water emulsion containing carbohydrate fatty-acid monosulphate esters, has shown potential to enhance influenza vaccine responses, but its mechanisms in humans remain unclear. We performed …

be, nl, us (code pays fourni par la source)

A Novel Carbohydrate Fatty-Acid Monosulphate Ester, Squalane-in-Water Adjuvant Is Safe and Enhances Inactivated Influenza Vaccine Immunogenicity in Older Adults

Valentino D’Onofrio, Bart Jacobs, Azhar Alhatemi, Simon De Gussem et autres

Influenza vaccines are the primary strategy to prevent severe influenza disease; however, their efficacy is often suboptimal, particularly in older adults (OAs). LiteVax Adjuvant (LVA), a novel adjuvant containing carbohydrate fatty-acid monosulphate ester (CMS) as the active ingredient, has demonstrated a favourable …

be, it (code pays fourni par la source)